25.1 C
New York
Tuesday, June 2, 2026

Tag: tablet

newssourceFORcompanyinformationcontent1marketreleases

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.

Verizon Gears Up for Back-to-School with a Weekend of Savings, Expert Advice & Essential Tech for Families

Visit any Verizon store for free devices, discounts, and digital wellness tools 
Visit any Verizon store for free devices, discounts, and digital wellness tools

Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction

www.freyapharmasolutions.com

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data  PITTSBURGH, Aug. 1, 2025 /PRNewswire/...

NeuroSense Provides Business Update and Progress for the First Half of 2025

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided...

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.

Noteorius Launches Smart Notebook that Fights Digital Distraction

Minimalist Design, Always on Dark Mode Help Increase Mental Focus and Clarity KENT, Ohio, July 29, 2025 /PRNewswire/ -- In an era where screens dominate...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTablet

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers